Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY +4.56%67 Days Sales Outstanding is 83.20 as of Jun. 2026, which is 15% above its 10-year median of 72.05. GuruFocus rates SWOBY with a GF Scoreâ„¢ of 67/100 and a GF Valueâ„¢ of $18.43 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 947 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 51.85% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Days Sales Outstanding Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Days Sales Outstanding falls into.
Swedish Orphan Biovitrum AB Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a Days Sales Outstanding of 83.20 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 15% above median its historical median of 72.05. Over the past decade, Swedish Orphan Biovitrum AB's Days Sales Outstanding has ranged from 42.78 to 89.58. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #491 out of 947 companies in the Drug Manufacturers industry, placing it in the top 51.8%.
Is Swedish Orphan Biovitrum AB's Days Sales Outstanding too high?
Swedish Orphan Biovitrum AB's current Days Sales Outstanding of 83.20 is 15% above median its 10-year median of 72.05. Over the past 10 years, this metric has ranged from a low of 42.78 to a high of 89.58. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Swedish Orphan Biovitrum AB's value of 83.20 is 15.6% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #491 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Scoreâ„¢ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #491 out of 947 companies for Days Sales Outstanding. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Swedish Orphan Biovitrum AB's value of 83.20 is 15.6% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own Days Sales Outstanding has ranged from 42.78 to 89.58 over the past decade. While the company's 10-year median is 72.05 vs. the industry median of 71.98, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Days Sales Outstanding of 83.20 is 15.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Days Sales Outstanding is 83.20, which is 15% above median its own 10-year median of 72.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.43, compared to a current price of $24.31 — trading 31.9% above its estimated fair value. The current Days Sales Outstanding is 83.20, which is 15% above median its 10-year median of 72.05 and 15.6% above the Drug Manufacturers industry median of 71.98. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Days Sales Outstanding is 83.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $24.31 is trading 31.9% above its estimated GF Value™ of $18.43.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
Days Sales Outstanding: 83.20 (15% above median its 10-year median of 72.05)
GF Value™: $18.43 vs. price of $24.31 (31.9% above fair value)
Industry Position: 15.6% above the Drug Manufacturers median (#491 of 947)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
